2. Jung C., Brubaker L. The etiology and management of recurrent urinary tract infections in postmenopausal women. Climacteric. 2019;22(3):242–249. Doi: 10.1080/13697137.2018.1551871.

3. Magistro G., Marcon J., Schubert S., Gratzke C., Stief C.G. Pathogenese der Harnwegsinfektion: Ein Update

4. McLellan L.K., Hunstad D.A. Urinary Tract Infection: Pathogenesis and Outlook. Trends Mol Med. 2016;22(11):946–957. Doi: 10.1016/j.molmed.2016.09.003.

5. Finucane T.E. ‘Urinary Tract Infection’ and the Microbiome. Am J Med. 2017;130(3):e97–e98. Doi: 10.1016/j.amjmed.2016.08.018.

6. Lee S.J. Recent advances in managing lower urinary tract infections. F1000Res. 2018;7:F1000 Faculty Rev-1964. Published 2018 Dec 21. Doi: 10.12688/f1000research.16245.1

7. Kogan M.I., Naboka Yu.L., Ibishev Kh.S., Gudima I.A. The non-sterility of the urine of a healthy person is a new paradigm in medicine. Urologiia. 2014;5:48–52. Russian (Коган М.И., Набока Ю.Л., Ибишев Х.С., Гудима И.А. Нестерильность мочи здорового человека – новая парадигма в медицине. Урология. 2014;5:48–52).

8. Davis N., Flood H.D.The Pathogenesis of Urinary Tract Infections. In book: Clinical Management of Complicated Urinary Tract Infection. 2011. Doi: 10.5772/22308.

9. Kato T., Honda Y., Kurita Y., et al. Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers. PLoS One. 2017;12(4):e0175626. Doi: 10.1371/journal.pone.0175626.

10. Tassopoulos A., Chalkias A., Papalois A., Iacovidou N., Xanthos T. The effect of antioxidant supplementation on bacterial translocation after intestinal ischemia and reperfusion. Redox Rep. 2017;22(1):1–9. Doi: 10.1080/13510002.2016.1229893.

11. Drolia R., Tenguria S., Durkes A.C., Turner J.R., Bhunia A.K. Listeria Adhesion Protein Induces Intestinal Epithelial Barrier Dysfunction for Bacterial Translocation. Cell Host Microbe. 2018;23(4):470–484.e7. Doi: 10.1016/j.chom.2018.03.004.

12. Alexopoulou A., Agiasotelli D., Vasilieva L.E., Dourakis S.P. Bacterial translocation markers in liver cirrhosis. Ann Gastroenterol. 2017;30(5):486–497. Doi: 10.20524/aog.2017.0178.

13. Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion. 2002;66(4):246–256. Doi: 10.1159/000068362.

14. Tsien C., Antonova L., Such J., Garcia-Martinez I., Wong F. Impact of Bacterial Translocation on Sarcopenia in Patients with Decompensated Cirrhosis. Nutrients. 2019;11(10):2379. Doi: 10.3390/nu11102379.

15. Pedersen G. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium. Dan Med J. 2015;62(1):B4973.

16. MacDermott R.P. Alterations of the mucosal immune system in inflammatory bowel disease. J Gastroenterol. 1996;31(6):907–916. Doi: 10.1007/BF02358624.

17. Kulchavenya E.V., Breusov A.A. Long-term results of immunoprophylaxis of infections of the urogenital tract. Urology Bulletin. 2013;2:3–9. Russian (Кульчавеня Е.В., Бреусов А.А. Отдаленные результаты иммунопрофилактики инфекций урогенитального тракта. Вестник урологии. 2013;2:3–9).

18. Oyama N., Winek K., Bäcker-Koduah P., et al. Exploratory Investigation of Intestinal Function and Bacterial Translocation After Focal Cerebral Ischemia in the Mouse. Front Neurol. 2018;9:937. Doi: 10.3389/fneur.2018.00937.

19. Crapser J., Ritzel R., Verma R., et al. Ischemic stroke induces gut permeability and enhances bacterial translocation leading to sepsis in aged mice. Aging (Albany NY). 2016;8(5):1049–1063. Doi: 10.18632/aging.100952.

20. Kulchavenya E.V. How to improve the quality of life of patients with chronic prostatitis. Spravochnik poliklinicheskogo vracha. 2019;04:64–69. Russian (Кульчавеня Е.В. Как повысить качество жизни больных хроническим простатитом. Справочник поликлинического врача. 2019;04:64–69).

21. Karl J.P., Margolis L.M., Madslien E.H., et al. Changes in intestinal microbiota composition and metabolism coincide with increased intestinal permeability in young adults under prolonged physiological stress. Am J Physiol Gastrointest Liver Physiol. 2017;312(6):G559–G571. Doi: 10.1152/ajpgi.00066.2017.

22. Yoshikawa K., Kurihara C., Furuhashi H., et al. Psychological stress exacerbates NSAID-induced small bowel injury by inducing changes in intestinal microbiota and permeability via glucocorticoid receptor signaling. J Gastroenterol. 2017;52(1):61–71. Doi: 10.1007/s00535-016-1205.

23. Slyepchenko A., Maes M., Jacka F.N., et al. Gut Microbiota, Bacterial Translocation, and Interactions with Diet: Pathophysiological Links between Major Depressive Disorder and Non-Communicable Medical Comorbidities. Psychother Psychosom. 2017;86(1):31–46. Doi: 10.1159/000448957.

24. Slyepchenko A., Maes M., Machado-Vieira R., et al. Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes. Curr Pharm Des. 2016;22(40):6087–6106. Doi: 10.2174/1381612822666160922165706.

25. Sprooten R.T.M., Lenaerts K., Braeken D.C.W., et al. Increased Small Intestinal Permeability during Severe Acute Exacerbations of COPD. Respiration. 2018;95(5):334–342. Doi: 10.1159/000485935.

26. Qi Y., Goel R., Kim S., et al. Intestinal Permeability Biomarker Zonulin is Elevated in Healthy Aging. J Am Med Dir Assoc. 2017;18(9):810.e1–810.e4. Doi: 10.1016/j.jamda.2017.05.018.

27. Knoop K.A., McDonald K.G., Kulkarni D.H., Newberry R.D. Antibiotics promote inflammation through the translocation of native commensal colonic bacteria. Gut. 2016;65(7):1100–1109. Doi: 10.1136/gutjnl-2014-309059.

28. De-Souza D.A., Greene L.J. Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. Crit Care Med. 2005;33(5):1125–1135. Doi: 10.1097/01.ccm.0000162680.52397.97.

29. Naber K.G., Kulchavenya E., Bichler K.-H., Wagenlehner F.M.E. Urogenital tuberkulose und Schistosomiasis (Bilharziose). Der Urologe 2018; 57:1191–1199. https://doi.org/10.1007/s00120-018-0760-x

30. Kulchavenya E., Naber K., Bjerklund Johansen T.E. Urogenital tuberculosis: classification, diagnosis, and treatment. European Urology Supplement, 2016;15(4): 112–121.

31. Birder L., Andersson K.E. Urothelial signaling. Physiol Rev. 2013;93(2):653–680. Doi: 10.1152/physrev.00030.2012.

32. Chai T.C., Russo A., Yu S., Lu M. Mucosal signaling in the bladder. Auton Neurosci. 2016;200:49–56. Doi: 10.1016/j.autneu.2015.08.009.

33. Lacerda Mariano L., Ingersoll M.A. The immune response to infection in the bladder. Nat Rev Urol (2020). https://doi.org/10.1038/s41585-020-0350-8

34. Winder M., Tobin G., Zupančič D., Romih R. Signalling molecules in the urothelium. Biomed Res Int. 2014;2014:297295. Doi: 10.1155/2014/297295.

35. Fry C.H., Vahabi B. The Role of the Mucosa in Normal and Abnormal Bladder Function. Basic Clin Pharmacol Toxicol. 2016;119 Suppl 3(Suppl 3):57–62. Doi: 10.1111/bcpt.12626.

36. Hurst R.E., Greenwood-Van Meerveld B., Wisniewski A.B., et al. Increased bladder permeability in interstitial cystitis/painful bladder syndrome. Transl Androl Urol. 2015;4(5):563–571. Doi: 10.3978/j.issn.2223–4683.2015.10.03.

37. Berdichevsky B.A. Autobacteria, stress and humans (anthology of one observation). M.: Medical book, 2001. 208 p. Russian (Бердичевский Б.А. Аутобактерии, стресс и человек (антология одного наблюдения). М.: Медицинская книга, 2001. 208 с.).

38. Manfredo Vieira S., Hiltensperger M., Kumar V., et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans

39. Kunst M.A., Yakupova S.P., Zinkevich O.D. et al. The role of microbial infection and intestinal permeability in the pathogenesis of rheumatoid arthritis. Practical medicine. 2014;4(80):56–58. Russian (Кунст М.А., Якупова С.П., Зинкевич О.Д. с соавт. Роль микробной инфекции и проницаемости кишечника в патогенезе ревматоидного артрита. Практическая медицина. 2014;4(80):56–58).

40. Ivashkin V.T., Trukhmanov A.S., Gonik M.I. The use of rebamipide in the treatment of gastroesophageal reflux disease. Terapevticheskii arkhiv. 2020;92(4):98–104. Russian (Ивашкин В.Т., Трухманов А.С., Гоник М.И. Применение ребамипида в лечении гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2020;92(4):98–104). Doi: 10.26442/00403660.2020.04.000568.

41. Fujimoto A., Uraoka T., Nishizawa T., et al. Rebamipide solution: a novel submucosal injection material to promote healing speed and healing quality of ulcers induced by endoscopic submucosal dissection. Gastrointest Endosc. 2018;87(4):1114–1120. Doi: 10.1016/j.gie.2017.09.040.

42. Arakawa T., Kobayashi K., Yoshikawa T., Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43(9 Suppl):5S–13S.

43. Arakawa T., Higuchi K., Fujiwara Y., et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50(Suppl.1):S3–S11. Doi: 10.1007/s10620-005-2800-9.

44. Otani K., Tanigawa T., Watanabe T., et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22–28. Doi: 10.1159/000452356.

45. Zvyaglova M.Yu., Knyazev O.V., Parfenov A.I. Rebamipide: prospects for application in gastroenterology and not only. Terapevticheskii arkhiv. 2020;92(2):104–111. Russian (Звяглова М.Ю., Князев О.В., Парфенов А.И. Ребамипид: перспективы применения в гастроэнтерологии и не только. Терапевтический архив. 2020;92(2):104–111). Doi: 10.26442/00403660.2020.02.000569.

46. Kim S.K., Choe J.Y., Park K.Y. Rebamipide Suppresses Monosodium Urate Crystal-Induced Interleukin-1β Production Through Regulation of Oxidative Stress and Caspase-1 in THP-1 Cells. Inflammation. 2016;39(1):473–482. Doi: 10.1007/s10753-015-0271-5.

47. Kim J.I., Park H.J., Park N.C. Absorption, Excretion and Antioxidative Effect of Rebamipide on Reproductive Organ. Korean J Fertil Steril. 2005;32(4):301–314.

48. Yokota T., Ogawa T., Takahashi S., et al. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study. BMC Cancer. 2017;17(1):314. Doi: 10.1186/s12885-017-3295-4.

49. Nakashima T., Uematsu N., Sakurai K. Intra-oral administration of rebamipide liquid prevents tongue injuries induced by X-ray irradiation in rats. Support Care Cancer. 2017;25(7):2205–2213. Doi: 10.1007/s00520-017-3626-7.

50. Park S., Park S.Y., Kim Y.J., et al. Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2016;40(3):240–247. Doi: 10.4093/dmj.2016.40.3.240.

51. Chin H.J., Oh Y.K., Jung Y.C., Lim C.S., Ahn C., Han J.S., Kim S.-K.,Lee J.S. The phase II clinical study of rebamipide (mucosta tablet) on chronic glomerulonephritis patients. Journal of Korean Society for Clinical Pharmacology and Therapeutics. 5(2):170–182.

52. Igarashi T., Kobayashi M., Yaguchi C., Fujimoto C., Suzuki H., Takahashi H. Efficacy of Rebamipide Instillation for Contact Lens Discomfort With Dry Eye. Eye Contact Lens. 2018;44 Suppl 2(2):S137–S142. Doi: 10.1097/ICL.0000000000000438.

53. Shrivastava S., Patkar P., Ramakrishnan R., Kanhere M., Riaz Z. Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes. Oman J Ophthalmol. 2018;11(3):207–212. Doi: 10.4103/ojo.OJO_29_2017.

54. Tajima K., Hattori T., Takahashi H., et al. Rebamipide suppresses TNF-α production and macrophage infiltration in the conjunctiva. Vet Ophthalmol. 2018;21(4):347–352. Doi: 10.1111/vop.12510.

55. Suzuki Y., Hasegawa M., Matsui Y., et al. Intra-articular injection of rebamipide prevents articular cartilage degeneration in murine post-traumatic osteoarthritis models. Mod Rheumatol. 2020;30(4):765–772. Doi: 10.1080/14397595.2019.1641912

56. Nanke Y., Kobashigawa T., Yago T., Kawamoto M., Yamanaka H., Kotake S.Rebamipide, an Amino Acid Analog of 2(1H)-Quinolinone, Inhibits the Formation of Human Osteoclasts. Biomed Res Int. 2016;2016:6824719. Doi: 10.1155/2016/6824719.

57. Sun M., Deng Z., Shi F., et al. Rebamipide-loaded chitosan nanoparticles accelerate prostatic wound healing by inhibiting M1 macrophage-mediated inflammation via the NF-κB signaling pathway. Biomater Sci. 2020;8(3):912–925. Doi: 10.1039/c9bm01512d.

58. Funahashi Y., Yoshida M., Yamamoto T., Majima T., Takai S., Gotoh M. Intravesical application of rebamipide suppresses bladder inflammation in a rat cystitis model. J Urol. 2014;191(4):1147–1152. Doi: 10.1016/j.juro.2013.11.026.

59. Funahashi Y., Yoshida M., Yamamoto T., Majima T., Takai S., Gotoh M.Intravesical application of rebamipide promotes urothelial healing in a rat cystitis model. J Urol. 2014;192(6):1864–1870. Doi: 10.1016/j.juro.2014.06.081.